Division of Hematology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: https://twitter.com/jlberrymd.
Division of Hematology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, USA. Electronic address: https://twitter.com/rushadpatell.
J Thromb Haemost. 2023 Apr;21(4):780-786. doi: 10.1016/j.jtha.2022.12.024. Epub 2023 Jan 2.
Most patients diagnosed with venous thromboembolism (VTE) are currently treated with direct oral anticoagulants (DOACs). Before an invasive procedure or surgery, clinicians face the challenging decision of how to best manage DOACs. Should the DOAC be held, for how long, and are there instances where bridging with other anticoagulants should be considered? Although clinical trials indicate that most patients taking DOACs for atrial fibrillation do not require bridging anticoagulation, the optimal strategy for patients with a history of VTE is undefined. In this review, we present a case-based discussion for DOAC interruption perioperatively in patients receiving anticoagulation for management of VTE.
大多数诊断为静脉血栓栓塞症(VTE)的患者目前接受直接口服抗凝剂(DOAC)治疗。在进行侵入性操作或手术前,临床医生面临着如何最佳管理 DOAC 的艰难决策。是否应停用 DOAC、停用多长时间,以及在哪些情况下应考虑使用其他抗凝剂桥接?尽管临床试验表明,大多数接受 DOAC 治疗心房颤动的患者不需要桥接抗凝,但 VTE 病史患者的最佳策略尚未确定。在这篇综述中,我们基于病例讨论了 VTE 抗凝治疗患者围手术期 DOAC 的中断问题。